Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05386810
Other study ID # PRO-msIPV-3001
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 5, 2020
Est. completion date July 20, 2023

Study information

Verified date May 2022
Source Sinovac Biotech Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study includes two parts.A clinical trial with a open-label to evaluate the safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) (2.5ml-5 doses)(hereinafter referred to as "msIPV")manufactured by Sinovac Biotech Co., Ltd. in adults, children and infants in partⅠ and a blinded,randomized and controlled clinical trial to evaluate the lot consistency immunogenicity, and safety of the msIPV in 2 months old infants in partⅡ.


Description:

This study includes two stages. A clinical trial with an open-label to evaluate the safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) (2.5ml-5 doses) (hereinafter referred to as "msIPV") in adults, children and infants in stageⅠ and a blinded, randomized and controlled clinical trial to evaluate the lot consistency immunogenicity, and safety of the msIPV in 2 months old infants in stage Ⅱ. A total of 1572 subjects including 24 adults aged 18-49 years,24 children aged 4 years,1524 infants aged 2 months will be enrolled. StagesⅠ:72 healthy subjects, including 24 adults,24 children and 24 infants will be enrolled. 24 adults and 24 children will receive one dose of vaccine and 24 infants will receive 4 doses of vaccine according to the primary immunization schedule of 0,1,2 months and booster immunization schedule of 18 months. StagesⅡ:1500 infants aged 2 months will be randomly divided into 5 groups (Experimental Vaccine-lot 1, Experimental Vaccine-lot 2, Experimental Vaccine-lot 3,IPV control group and single-dose sIPV control group) according to the ratio of 1:1:1:1:1. Subjects in 3 experimental groups will receive 5-dose sIPV produced by Sinovac for three lots, subjects in IPV control group will receive IPV produced by Pasteur, and subjects in single-dose sIPV control group will receive single-dose sIPV produced by Sinovac. All subjects will receive 4 doses of experimental or control vaccine according to the primary immunization schedule of 0,1,2 months, one dose of booster at 18 months of age.


Recruitment information / eligibility

Status Completed
Enrollment 1572
Est. completion date July 20, 2023
Est. primary completion date October 8, 2022
Accepts healthy volunteers No
Gender All
Age group 2 Months to 49 Years
Eligibility Inclusion Criteria: Inclusion criteria for adult subjects : - Healthy adults aged 18-49 days; - Proven legal identification; - The subject can understand and voluntarily sign the informed consent form. Inclusion criteria for children subjects : - Healthy children aged 4 years old; - Subjects who have completed primary immunization with 3 doses of sIPV vaccine; - Proven legal identification and vaccination certificate; - The subject and/or guardian can understand and voluntarily sign the informed consent form. Inclusion criteria for infant subjects: - Healthy infants aged 2 months (60~89 days) - Proven legal identification and vaccination certificate; - The subject and/or guardian can understand and voluntarily sign the informed consent form. Exclusion Criteria: Exclusion criteria for adult subjects: - Women aged 18 to 49 years, positive urine pregnancy test, pregnant women, breastfeeding women, or planning to become pregnant within 3 months; - Previous history of vaccination of sIPV vaccine; - Allergy history, history of asthma, including allergy history to vaccine or vaccine components, serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioneurotic edema or stomachache, etc; - Congenital malformation or developmental disorder, genetic defect, serious malnutrition, etc.; - Autoimmune disease or immunodeficiency/immunosuppression; - Thyroid disease or thyroidectomy history, absence of spleen, functional absence of spleen, and any conditions resulting in absence of spleen or splenectomy; - Serious chronic diseases, serious cardiovascular diseases, hypertension that cannot be controlled by drugs (systolic blood pressure > 140mmHg, diastolic blood pressure > 90mmHg), diabetes, liver and kidney diseases, malignant tumors, etc; - Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; - Medical diagnosis of coagulation abnormalities (such as coagulation factor deficiency, coagulation disorders, platelet abnormalities) or marked bruising or coagulation disorders; - Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months; - History of alcohol or drug abuse; - Receipt of blood products within in the past 3 months; - Receipt of other investigational drugs in the past 30 days; - Receipt of attenuated live vaccines in the past 14 days; - Receipt of inactivated or subunit vaccines in the past 7 days; - Acute diseases or acute exacerbation of chronic diseases in the past 7 days; - Axillary temperature >37.0°C; - According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial. Exclusion criteria for children subjects: - Have received 4 doses of sIPV vaccine; - History of polio; - Allergy history, history of asthma, including allergy history to vaccine or vaccine components, serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioneurotic edema or stomachache, etc; - Congenital malformation or developmental disorder, genetic defect, serious malnutrition, etc.; - Autoimmune disease or immunodeficiency/immunosuppression; - Thyroid disease or thyroidectomy history, absence of spleen, functional absence of spleen, and any conditions resulting in absence of spleen or splenectomy; - Suffering from serious cardiovascular diseases, diabetes, liver and kidney diseases, malignant tumors, etc; - Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; - Medical diagnosis of coagulation abnormalities (such as coagulation factor deficiency, coagulation disorders, platelet abnormalities) or marked bruising or coagulation disorders; - Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months; - History of alcohol or drug abuse; - Receipt of blood products within in the past 3 months; - Receipt of other investigational drugs in the past 30 days; - Receipt of attenuated live vaccines in the past 14 days; - Receipt of inactivated or subunit vaccines in the past 7 days; - Acute diseases or acute exacerbation of chronic diseases in the past 7 days; - Axillary temperature >37.0°C; - According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial. Exclusion criteria for infant subjects: - Previous history of vaccination of sIPV vaccine; - History of polio; - Allergy history, history of asthma, including allergy history to vaccine or vaccine components, serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioneurotic edema or stomachache, etc; - Preterm birth babies (delivered before 37 weeks gestation), low birth weight (girls with birth weight <2300g, boy with birth weight<2500 g); - History of dystocia, asphyxia and nervous system damage at birth; - Congenital malformation or developmental disorder, genetic defect, serious malnutrition, etc.; - Autoimmune disease or immunodeficiency/immunosuppression; - Thyroid disease or thyroidectomy history, absence of spleen, functional absence of spleen, and any conditions resulting in absence of spleen or splenectomy; - -Suffering from serious cardiovascular diseases, diabetes, liver and kidney diseases, malignant tumors, etc; - Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; - Medical diagnosis of coagulation abnormalities (such as coagulation factor deficiency, coagulation disorders, platelet abnormalities) or marked bruising or coagulation disorders; - Have received immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy); - Receipt of blood products ; - Receipt of other investigational drugs in the past 30 days; - Receipt of attenuated live vaccines in the past 14 days; - Receipt of inactivated or subunit vaccines in the past 7 days; - Acute diseases or acute exacerbation of chronic diseases in the past 7 days; - Axillary temperature >37.0°C; - According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Experimental vaccine
Sabin Inactivated Poliovirus Vaccine (Vero cell) (2.5ml)-investigational vaccine produced by Sinovac Biotech Co., Ltd. Inactivated Sabin poliovirus antigen (per 0.5ml): type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 2.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate,2 - phenoxyethanol for per injection.
IPV control vaccine
Inactivated Poliovirus Vaccine - control vaccine produced by Sanofi. Inactivated poliovirus antigens: Mahoney strain for type 1 (40DU), MEF-1 strain for type 2 (8DU), Saukett strains for type 3 (32DU) in 0.5 ml mixture of 2- phenoxyethanol,ethanol,formaldehyde,hanks199 medium (containing amino acids, mineral salts, vitamins, glucose, polysorbate 80 and water for injection),hydrochloric acid or sodium hydroxide (for pH value adjustment),trace amounts of antibiotics (neomycin, streptomycin and polymyxin B)for per injection.
single-person sIPV control vaccine
Sabin Inactivated Poliovirus Vaccine (Vero cell) (0.5ml) -control vaccine produced by Sinovac Biotech Co., Ltd. Inactivated Sabin poliovirus antigen: type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 0.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate for per injection.

Locations

Country Name City State
China Xiangfu District Center for Disease Prevention and Control Kaifeng Henan
China Xiangcheng County Center for Disease Control and Prevention Xuchang Henan

Sponsors (1)

Lead Sponsor Collaborator
Sinovac Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety index-incidence of adverse reactions Incidence of adverse reactions within 30 days after each dose Within 30 days after each dose
Primary Immunogenicity index-Geometric mean titers (GMT) GMT 30 days after primary immunization in msIPV vaccination group 30 days after primary immunization
Primary Immunogenicity index- seroconversion rate of neutralizing antibody Seroconversion rate of neutralizing antibody 30 days after primary immunization in combined experiment group and IPV control group 30 days after primary immunization
Secondary Safety index-incidence of adverse reactions Incidence of adverse reactions within 7 days after each dose Within 7 days after each dose
Secondary Safety index-the incidence of adverse reactions Incidence of SAE during the period of safety monitoring During the period of safety monitoring
Secondary Immunogenicity index- Neutralizing antibody positive rate and GMI Neutralizing antibody positive rate and GMI and percentage of subjects with antibody =1:64 30 days after primary immunization 30 days after primary immunization
Secondary Immunogenicity index- Neutralizing antibody positive rate Neutralizing antibody positive rate, percentage of subjects with antibody =1:64 and GMT before booster dose Before booster dose
Secondary Immunogenicity index-Neutralizing antibody positive rate,GMT and GMI Neutralizing antibody positive rate, percentage of subjects with antibody =1:64, GMT and GMI 30 days after booster dose 30 days after booster dose
See also
  Status Clinical Trial Phase
Completed NCT04989231 - An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Recruiting NCT03890497 - Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Completed NCT04693286 - Clinical Trial of Novel OPV2 Vaccine Phase 2
Completed NCT02847026 - Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study Phase 4
Completed NCT02189811 - Polio End-game Strategies - Poliovirus Type 2 Challenge Study Phase 4
Completed NCT01444781 - Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants Phase 3
Completed NCT01214889 - Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. Phase 3
Completed NCT00879827 - Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants Phase 3
Completed NCT01457495 - Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly Phase 2
Completed NCT02853929 - Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Phase 4
Completed NCT03614702 - Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV Phase 3
Terminated NCT04063150 - Immunogenicity of Intramuscular and Intradermal IPV Phase 4
Completed NCT04614597 - A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China
Completed NCT03239496 - A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV Phase 3
Completed NCT04544787 - A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates Phase 2
Completed NCT02985320 - Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine Phase 1/Phase 2
Completed NCT02291263 - Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine Phase 3
Completed NCT02274285 - DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants Phase 3